Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash

Edwards Lifesciences Corp

Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.
Consideration of ~$300M in cash; expected closing by end of 2024.
Innovalve to join TMTT product group; initial investment made in 2017.
Edwards' SAPIEN M3 TMVR system on track for European approval by end of 2025.
Acquisition aims to expand treatable mitral valve population with combined platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.